Canton Strategic Holdings (CNTN) Non-Current Assets (2025 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Non-Current Assets came in at $541.6 million in Q1 2026, up 7.93% on a QoQ basis from $501.8 million in Q4 2025.
Powered by 
Analysis
Canton Strategic Holdings (CNTN) Non-Current Assets (2025 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 2 years of Non-Current Assets data on file, last reported at $541.6 million in Q1 2026.
- Quarterly Non-Current Assets changed N/A year-over-year to $541.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (changed N/A YoY) and the FY2025 annual result came in at $501.8 million, changed N/A from the prior year.
- Non-Current Assets climbed to $541.6 million in Q1 2026, from $501.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $541.6 million in Q1 2026 to a low of $501.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | 523.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 523.35 Mn |
| Mar 31, 2026 | 541.57 Mn |
| Dec 31, 2025 | 501.76 Mn |